



**Notification of the Separation of the Overseas CRO Operation**

We would like to announce that, following a meeting of the board of directors on May 1st 2013, it has been agreed that our in-house Global Research company, which develops our overseas operations, will be spun off as a separate entity. With regards to methods employed for the separation, we intend to make announcements as soon as decisions are made.

**1. Separation of the Overseas CRO Operation**

With regards to our overseas CRO operation, in order to respond to the globalization of pharmaceutical companies, commercial activities have been carried out across the Asian region, in China, Hong Kong, Taiwan, Korea and Singapore, in addition to marketing activities in America, with our in-house Global Research company as the mainstay.

Including both overseas and domestic facets, the company has grown to include just under 200 employees, with annual sales of around ¥1.5 billion. Recognizing the need for greater internal and external unification of agile management and the clarification of profit responsibility, we will spin off this in-house company. From now on, this group of companies will aspire to the realization of a streamlined one-stop service that can meet the challenges of the diversifying needs and increasing sophistication of pharmaceutical companies. Dan Weng, current head of Global Research, is to be appointed head of this enterprise.

(1) Company name	EPS International Co., Ltd. (provisional name)
(2) Representative	Directors & Chairman: Yan Hao President & CEO: Dan Weng
(3) Business Description	Overseas CRO, SMO and related IT operations
(4) Ownership Ratio	EPS Corporation 100%
(5) Location of Head Office	Shinjuku-ku, Tokyo
(6) Capital	Unconfirmed
(7) Date of Foundation	July 1st 2013 (planned)



(8) Objectives of Separation

- Speed up decision-making and determine unified management strategies for the overseas CRO operation.
- Profitable growth (Internal growth and mergers and acquisitions)
- Clarification of results and responsibilities.
- Make use of diverse human resources.

2. Effects on Consolidated Business Performance in this Term

At this point in time, effects on consolidated business performance in this term are forecast to be negligible. In the event that effects on performance are anticipated, timely announcements will be made at the defined stage.